Treatment of MIBC

Treatment of Muscle-Invasive Bladder Cancer (MIBC)

Abbreviations: MIBC=muscle-invasive bladder cancer; TURBT= trans-uretheral resection.

References: 1. Aminoltejari K, Black PC. Transl Androl Urol. 2020;9:3073–3081. 2. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Bladder Cancer.V.4.2024. ©National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed July 10, 2024. To view the most recent and complete version of the guideline, go online to NCCN.org. 3. European Association of Urology. EAU guidelines on Muscle-invasive and Metastatic Bladder Cancer. 2024 Limited Update April 2024. https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Muscle-Invasive-and-Metastatic-Bladder-Cancer-2024.pdf. Accessed July 2024. 4. Powles T, et al. Ann Oncol. 2022;33:244–258. 5. Esteban-Villarrubia J, et al. Cancers (Basel). 2023;15:566. 6. Mari A, et al. World J Urol. 2018;36:157–170. 7. Leow JJ, et al. Hematol Oncol Clin North Am. 2015;29:301–318.

Treatment of MIBC

The treatment of MIBC is complex and includes the removal of tumour tissue while limiting disease progression and the development of metastases.1–4

Radical cystectomy involves the complete removal of the bladder and represents the current standard of care for MIBC.1,3,4

Radiation therapy can be used as an alternative to surgery or in combination with chemotherapy with the aim to shrink the tumour.2–4

Cisplatin-based chemotherapy

  • Neoadjuvant chemotherapy may be used before surgery to shrink the tumour, making it easier to remove, and reducing the risk of metastases5–7
  • Adjuvant chemotherapy may be given after surgery to reduce the risk of micro-metastases and disease recurrence5,6
  • Perioperative chemotherapy is chemotherapy given both before and after surgery to shrink the tumour and reduce the risk of post-operative disease recurrence7

Chemoradiotherapy combines radiation therapy and chemotherapy to shrink the tumour and reduce the risk of disease recurrence and metastases.2–4

Bladder preservation techniques may be used and can include trans-uretheral resection (TURBT), chemotherapy and radiation.2–4

Immunotherapy may be used in the adjuvant setting to enhance the anti-tumour immune response.2–4

Abbreviations: MIBC=muscle-invasive bladder cancer; TURBT= trans-uretheral resection.

References: 1. Aminoltejari K, Black PC. Transl Androl Urol. 2020;9:3073–3081. 2. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Bladder Cancer.V.4.2024. ©National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed July 10, 2024. To view the most recent and complete version of the guideline, go online to NCCN.org. 3. European Association of Urology. EAU guidelines on Muscle-invasive and Metastatic Bladder Cancer. 2024 Limited Update April 2024. https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Muscle-Invasive-and-Metastatic-Bladder-Cancer-2024.pdf. Accessed July 2024. 4. Powles T, et al. Ann Oncol. 2022;33:244–258. 5. Esteban-Villarrubia J, et al. Cancers (Basel). 2023;15:566. 6. Mari A, et al. World J Urol. 2018;36:157–170. 7. Leow JJ, et al. Hematol Oncol Clin North Am. 2015;29:301–318.